Profusa Acquires BioInsights' PanOmics Platform for $30 Million
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 06 2026
0mins
Profusa Inc's stock fell by 9.60% as it crossed below the 5-day SMA amid strong gains in the broader market, with the Nasdaq-100 up 2.92% and the S&P 500 up 2.37%.
The company has signed a Letter of Intent to acquire BioInsights' PanOmics multi-omics diagnostics platform for $30 million, which is expected to enhance its market position in biosensing and precision medicine. This acquisition will also provide access to clinical samples through a partnership with Mayo Clinic, facilitating accelerated development in pancreatic cancer monitoring and unlocking significant commercial value.
This strategic move positions Profusa to tap into a lucrative market opportunity, with over 13,000 pancreatic resections performed annually in the U.S., representing a potential $26 million revenue stream. The acquisition is anticipated to drive growth and innovation in the company's diagnostics capabilities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PFSA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PFSA
About PFSA
Profusa, Inc. is a commercial stage digital health company. The Company is engaged in the development of a new generation of biointegrated sensors that potentially empower the individual with the ability to monitor their body chemistry. The Company’s technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. Its first clinical offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels in various regions of interest, both acutely and long-term. The Lumee Oxygen Platform has been designed for use in applications where monitoring of compromised tissue is beneficial, such as peripheral artery disease that results in narrowing of blood vessels and reduced blood flow to the lower limbs; chronic wounds (diabetic ulcers, pressure sores) that do not heal properly; and reconstructive surgery.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Profusa Implements 1-for-25 Reverse Stock Split
- Reverse Stock Split Announcement: Profusa, Inc. has announced a 1-for-25 reverse stock split, consolidating every 25 shares into one, aimed at boosting share price to attract investor interest, despite a current decline of 28.08% in stock value.
- Declining Trading Performance: Following the reverse split announcement, Profusa's stock closed at $0.09 on February 7, 2026, and further dropped by 3.85% in the overnight market, indicating market concerns regarding the company's outlook.
- Changes in Capital Structure: Post-split, the outstanding shares will decrease from approximately 13.2 million to about 0.53 million, while authorized shares remain at 601 million, potentially affecting investor perceptions of the company's equity.
- Market Volatility: Over the past year, Profusa's stock has fluctuated between $0.08 and $412.50, reflecting the high-risk, high-reward nature of the biotech sector, necessitating careful evaluation of its future growth potential by investors.
See More
Profusa Implements 1-for-25 Reverse Stock Split
- Reverse Split Implementation: Profusa, Inc. will execute a 1-for-25 reverse stock split effective July 7, 2026, reducing outstanding shares from approximately 13.2 million to 530,000, which is expected to significantly enhance the per-share value while maintaining the par value unchanged.
- Shareholder Rights Assurance: The company emphasizes that the split will not affect shareholder rights beyond the adjustment in share count, with authorized shares remaining at 601 million, ensuring that overall shareholder interests are preserved.
- Recent Stock Price Volatility: Prior to the reverse split, PFSA's stock closed at $0.09 on Thursday, down 28.08% from the previous trading day, and continued to decline by 3.32% in after-hours trading, indicating market concerns regarding the company's outlook.
- Technological Development Context: Based in Berkeley, California, Profusa focuses on developing tissue-integrated biosensors aimed at delivering personalized, medical-grade data for clinical and consumer applications, and the reverse split may be intended to enhance market attention towards its innovative technology.
See More
Profusa Implements 1-for-25 Reverse Stock Split
- Reverse Stock Split Announcement: Profusa has announced a 1-for-25 reverse stock split effective July 7, 2026, which will reduce outstanding shares from approximately 13.2 million to about 530,000, aiming to enhance the stock price to attract more investor interest.
- Impact on Shareholders: While reverse splits are often seen as a strategy to improve stock prices, the company's shares have already declined over 31%, indicating market concerns about its future prospects, which may affect shareholder confidence and investment decisions.
- Authorized Shares Unchanged: The reverse stock split will not alter the number of authorized shares, allowing the company to maintain flexibility for future financing or equity-related actions, which is crucial for navigating market changes.
- Market Reaction Analysis: The implementation of the reverse stock split may trigger short-term market volatility, and investors should monitor the company's subsequent financial performance and strategic adjustments to assess its long-term investment value.
See More
Profusa Announces 1-for-25 Reverse Stock Split Plan
- Stock Split Announcement: Profusa plans to implement a 1-for-25 reverse stock split effective July 7, 2026, reducing outstanding shares from approximately 13.2 million to about 530,000, aimed at addressing persistent low stock prices.
- Poor Stock Performance: Since April 10, PFSA shares have failed to breach the critical $1 level, crashing 28% on Thursday to hit a record low, indicating market concerns regarding the company's future viability.
- Shareholder Support: Last month, Profusa's shareholders voted to approve one or more reverse splits over the next two years at ratios between 1-for-5 and 1-for-200, with the final ratio to be determined by the board, reflecting shareholder confidence in the restructuring efforts.
- Acquisition Plans: Profusa is looking to enhance its diagnostic capabilities by acquiring the PanOmics molecular diagnostics platform from BioInsights for approximately $30 million, which will complement its real-time biosensing technology and support new applications, particularly in pancreatic cancer monitoring.
See More
Profusa Announces 1-for-25 Reverse Stock Split
- Reverse Stock Split Announcement: Profusa has announced a 1-for-25 reverse stock split effective July 7, 2026, which will consolidate approximately 13.2 million shares into about 530,000 shares, aiming to increase the stock price to attract more investor interest.
- Exchange Changes: Following the reverse split, Profusa's common stock will open on the Nasdaq Global Market under the existing ticker symbol 'PFSA' but with a new CUSIP number 74319X 306, indicating a structural adjustment while maintaining market recognition.
- Shareholder Rights Protection: During the reverse stock split, no fractional shares will be issued; instead, shareholders entitled to fractional shares will receive cash compensation, ensuring that shareholder rights are preserved and not adversely affected.
- Long-term Strategic Positioning: This reverse stock split aims to enhance Profusa's market image and shareholder confidence, further driving the development of its digital health technology platform and strengthening its competitive position in the biosensor field.
See More
Profusa Submits CE Mark Application for Lumee Oxygen Platform
- CE Mark Progress: Profusa has submitted its response package to GMED for the Lumee Oxygen Platform, marking a significant milestone in the MDR conformity assessment process aimed at obtaining CE Mark certification to support its commercialization strategy in Europe.
- Technical Documentation Updates: The response package includes updates on technical documentation, quality system evidence, and clinical evaluation activities, demonstrating the company's ongoing efforts to meet regulatory requirements, thereby enhancing its competitive position in the market.
- Real-Time Monitoring Capability: The Lumee Oxygen Platform is designed to provide continuous, real-time monitoring of tissue oxygen levels through its proprietary tissue-integrated biosensor technology, addressing clinicians' needs for objective tissue perfusion data that may improve patient monitoring and treatment decision-making.
- Future Outlook: Although the CE Mark review process is ongoing, Profusa is committed to supporting the review and providing updates on significant regulatory milestones, reflecting its confidence in future product launches and keen insight into market demands.
See More
Profusa Implements 1-for-25 Reverse Stock Split
- Reverse Stock Split Announcement: Profusa, Inc. has announced a 1-for-25 reverse stock split, consolidating every 25 shares into one, aimed at boosting share price to attract investor interest, despite a current decline of 28.08% in stock value.
- Declining Trading Performance: Following the reverse split announcement, Profusa's stock closed at $0.09 on February 7, 2026, and further dropped by 3.85% in the overnight market, indicating market concerns regarding the company's outlook.
- Changes in Capital Structure: Post-split, the outstanding shares will decrease from approximately 13.2 million to about 0.53 million, while authorized shares remain at 601 million, potentially affecting investor perceptions of the company's equity.
- Market Volatility: Over the past year, Profusa's stock has fluctuated between $0.08 and $412.50, reflecting the high-risk, high-reward nature of the biotech sector, necessitating careful evaluation of its future growth potential by investors.
See More
Profusa Implements 1-for-25 Reverse Stock Split
- Reverse Split Implementation: Profusa, Inc. will execute a 1-for-25 reverse stock split effective July 7, 2026, reducing outstanding shares from approximately 13.2 million to 530,000, which is expected to significantly enhance the per-share value while maintaining the par value unchanged.
- Shareholder Rights Assurance: The company emphasizes that the split will not affect shareholder rights beyond the adjustment in share count, with authorized shares remaining at 601 million, ensuring that overall shareholder interests are preserved.
- Recent Stock Price Volatility: Prior to the reverse split, PFSA's stock closed at $0.09 on Thursday, down 28.08% from the previous trading day, and continued to decline by 3.32% in after-hours trading, indicating market concerns regarding the company's outlook.
- Technological Development Context: Based in Berkeley, California, Profusa focuses on developing tissue-integrated biosensors aimed at delivering personalized, medical-grade data for clinical and consumer applications, and the reverse split may be intended to enhance market attention towards its innovative technology.
See More
Profusa Implements 1-for-25 Reverse Stock Split
- Reverse Stock Split Announcement: Profusa has announced a 1-for-25 reverse stock split effective July 7, 2026, which will reduce outstanding shares from approximately 13.2 million to about 530,000, aiming to enhance the stock price to attract more investor interest.
- Impact on Shareholders: While reverse splits are often seen as a strategy to improve stock prices, the company's shares have already declined over 31%, indicating market concerns about its future prospects, which may affect shareholder confidence and investment decisions.
- Authorized Shares Unchanged: The reverse stock split will not alter the number of authorized shares, allowing the company to maintain flexibility for future financing or equity-related actions, which is crucial for navigating market changes.
- Market Reaction Analysis: The implementation of the reverse stock split may trigger short-term market volatility, and investors should monitor the company's subsequent financial performance and strategic adjustments to assess its long-term investment value.
See More
Profusa Announces 1-for-25 Reverse Stock Split Plan
- Stock Split Announcement: Profusa plans to implement a 1-for-25 reverse stock split effective July 7, 2026, reducing outstanding shares from approximately 13.2 million to about 530,000, aimed at addressing persistent low stock prices.
- Poor Stock Performance: Since April 10, PFSA shares have failed to breach the critical $1 level, crashing 28% on Thursday to hit a record low, indicating market concerns regarding the company's future viability.
- Shareholder Support: Last month, Profusa's shareholders voted to approve one or more reverse splits over the next two years at ratios between 1-for-5 and 1-for-200, with the final ratio to be determined by the board, reflecting shareholder confidence in the restructuring efforts.
- Acquisition Plans: Profusa is looking to enhance its diagnostic capabilities by acquiring the PanOmics molecular diagnostics platform from BioInsights for approximately $30 million, which will complement its real-time biosensing technology and support new applications, particularly in pancreatic cancer monitoring.
See More
Profusa Announces 1-for-25 Reverse Stock Split
- Reverse Stock Split Announcement: Profusa has announced a 1-for-25 reverse stock split effective July 7, 2026, which will consolidate approximately 13.2 million shares into about 530,000 shares, aiming to increase the stock price to attract more investor interest.
- Exchange Changes: Following the reverse split, Profusa's common stock will open on the Nasdaq Global Market under the existing ticker symbol 'PFSA' but with a new CUSIP number 74319X 306, indicating a structural adjustment while maintaining market recognition.
- Shareholder Rights Protection: During the reverse stock split, no fractional shares will be issued; instead, shareholders entitled to fractional shares will receive cash compensation, ensuring that shareholder rights are preserved and not adversely affected.
- Long-term Strategic Positioning: This reverse stock split aims to enhance Profusa's market image and shareholder confidence, further driving the development of its digital health technology platform and strengthening its competitive position in the biosensor field.
See More
Profusa Submits CE Mark Application for Lumee Oxygen Platform
- CE Mark Progress: Profusa has submitted its response package to GMED for the Lumee Oxygen Platform, marking a significant milestone in the MDR conformity assessment process aimed at obtaining CE Mark certification to support its commercialization strategy in Europe.
- Technical Documentation Updates: The response package includes updates on technical documentation, quality system evidence, and clinical evaluation activities, demonstrating the company's ongoing efforts to meet regulatory requirements, thereby enhancing its competitive position in the market.
- Real-Time Monitoring Capability: The Lumee Oxygen Platform is designed to provide continuous, real-time monitoring of tissue oxygen levels through its proprietary tissue-integrated biosensor technology, addressing clinicians' needs for objective tissue perfusion data that may improve patient monitoring and treatment decision-making.
- Future Outlook: Although the CE Mark review process is ongoing, Profusa is committed to supporting the review and providing updates on significant regulatory milestones, reflecting its confidence in future product launches and keen insight into market demands.
See More
